Annual Revenue
$131.31 M
-$64.93 M-33.09%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual revenue is currently $131.31 million, with the most recent change of -$64.93 million (-33.09%) on 31 December 2023. During the last 3 years, it has fallen by -$32.25 million (-19.72%). LGND annual revenue is now -47.78% below its all-time high of $251.45 million, reached on 31 December 2018.LGND Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$51.81 M
+$10.28 M+24.76%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly revenue is currently $51.81 million, with the most recent change of +$10.28 million (+24.76%) on 30 September 2024. Over the past year, it has increased by +$18.94 million (+57.64%). LGND quarterly revenue is now -42.46% below its all-time high of $90.04 million, reached on 30 June 2018.LGND Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$152.42 M
+$18.94 M+14.19%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM revenue is currently $152.42 million, with the most recent change of +$18.94 million (+14.19%) on 30 September 2024. Over the past year, it has dropped by -$1.17 million (-0.76%). LGND TTM revenue is now -39.47% below its all-time high of $251.79 million, reached on 30 September 2021.LGND TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.1% | +57.6% | -0.8% |
| 3 y3 years | -19.7% | -20.1% | -39.5% |
| 5 y5 years | -47.8% | +108.8% | -0.3% |
LGND Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -45.6% | at low | -20.1% | +96.5% | -39.5% | +28.8% |
| 5 y | 5 years | -47.8% | +9.2% | -38.8% | +108.8% | -39.5% | +38.6% |
| alltime | all time | -47.8% | +3201.8% | -42.5% | +167.2% | -39.5% | +470.7% |
Ligand Pharmaceuticals Incorporated Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $51.81 M(+24.8%) | $152.42 M(+14.2%) |
| June 2024 | - | $41.53 M(+34.1%) | $133.48 M(+12.8%) |
| Mar 2024 | - | $30.98 M(+10.2%) | $118.31 M(-9.9%) |
| Dec 2023 | $131.31 M(-33.1%) | $28.10 M(-14.5%) | $131.31 M(-14.5%) |
| Sept 2023 | - | $32.87 M(+24.7%) | $153.59 M(-14.6%) |
| June 2023 | - | $26.37 M(-40.0%) | $179.95 M(-11.7%) |
| Mar 2023 | - | $43.98 M(-12.7%) | $203.71 M(+3.8%) |
| Dec 2022 | $196.25 M(-18.8%) | $50.38 M(-14.9%) | $196.25 M(+7.4%) |
| Sept 2022 | - | $59.22 M(+18.1%) | $182.75 M(-3.0%) |
| June 2022 | - | $50.13 M(+37.3%) | $188.36 M(-15.5%) |
| Mar 2022 | - | $36.52 M(-1.0%) | $222.91 M(-7.7%) |
| Dec 2021 | $241.54 M(+47.7%) | $36.88 M(-43.1%) | $241.54 M(-4.1%) |
| Sept 2021 | - | $64.83 M(-23.4%) | $251.79 M(+10.0%) |
| June 2021 | - | $84.67 M(+53.5%) | $228.81 M(+23.3%) |
| Mar 2021 | - | $55.15 M(+17.0%) | $185.55 M(+13.4%) |
| Dec 2020 | $163.56 M(+36.0%) | $47.13 M(+12.6%) | $163.56 M(+14.0%) |
| Sept 2020 | - | $41.85 M(+1.0%) | $143.43 M(+13.5%) |
| June 2020 | - | $41.42 M(+24.9%) | $126.39 M(+14.9%) |
| Mar 2020 | - | $33.16 M(+22.8%) | $109.96 M(-8.6%) |
| Dec 2019 | $120.28 M(-52.2%) | $27.00 M(+8.8%) | $120.28 M(-21.3%) |
| Sept 2019 | - | $24.81 M(-0.7%) | $152.87 M(-12.0%) |
| June 2019 | - | $24.99 M(-42.5%) | $173.72 M(-27.2%) |
| Mar 2019 | - | $43.48 M(-27.0%) | $238.78 M(-5.0%) |
| Dec 2018 | $251.45 M(+78.2%) | $59.59 M(+30.5%) | $251.45 M(+3.8%) |
| Sept 2018 | - | $45.66 M(-49.3%) | $242.33 M(+5.3%) |
| June 2018 | - | $90.04 M(+60.3%) | $230.04 M(+36.9%) |
| Mar 2018 | - | $56.16 M(+11.3%) | $167.99 M(+19.1%) |
| Dec 2017 | $141.10 M(+29.5%) | $50.46 M(+51.2%) | $141.10 M(+9.5%) |
| Sept 2017 | - | $33.38 M(+19.2%) | $128.82 M(+10.0%) |
| June 2017 | - | $28.00 M(-4.3%) | $117.07 M(+7.8%) |
| Mar 2017 | - | $29.27 M(-23.4%) | $108.59 M(-0.3%) |
| Dec 2016 | $108.97 M(+51.5%) | $38.19 M(+76.6%) | $108.97 M(+18.5%) |
| Sept 2016 | - | $21.62 M(+10.7%) | $91.98 M(+4.4%) |
| June 2016 | - | $19.52 M(-34.2%) | $88.06 M(+1.3%) |
| Mar 2016 | - | $29.65 M(+39.9%) | $86.96 M(+20.9%) |
| Dec 2015 | $71.91 M(+11.4%) | $21.19 M(+19.7%) | $71.91 M(-2.5%) |
| Sept 2015 | - | $17.70 M(-3.9%) | $73.72 M(+3.8%) |
| June 2015 | - | $18.42 M(+26.1%) | $70.99 M(+12.4%) |
| Mar 2015 | - | $14.60 M(-36.5%) | $63.18 M(-2.1%) |
| Dec 2014 | $64.54 M(+31.8%) | $23.00 M(+53.6%) | $64.54 M(+14.7%) |
| Sept 2014 | - | $14.97 M(+41.1%) | $56.27 M(+3.6%) |
| June 2014 | - | $10.61 M(-33.5%) | $54.31 M(+1.9%) |
| Mar 2014 | - | $15.96 M(+8.3%) | $53.28 M(+8.8%) |
| Dec 2013 | $48.97 M(+56.0%) | $14.74 M(+13.3%) | $48.97 M(+2.3%) |
| Sept 2013 | - | $13.01 M(+35.8%) | $47.87 M(+16.1%) |
| June 2013 | - | $9.58 M(-17.8%) | $41.24 M(+10.3%) |
| Mar 2013 | - | $11.65 M(-14.6%) | $37.40 M(+19.2%) |
| Dec 2012 | $31.39 M(+4.5%) | $13.63 M(+113.9%) | $31.39 M(+2.3%) |
| Sept 2012 | - | $6.38 M(+11.0%) | $30.69 M(+2.1%) |
| June 2012 | - | $5.74 M(+1.9%) | $30.05 M(-5.4%) |
| Mar 2012 | - | $5.64 M(-56.4%) | $31.78 M(+5.8%) |
| Dec 2011 | $30.04 M(+27.6%) | $12.94 M(+125.3%) | $30.04 M(+42.8%) |
| Sept 2011 | - | $5.74 M(-23.1%) | $21.04 M(-8.9%) |
| June 2011 | - | $7.46 M(+91.6%) | $23.10 M(+7.6%) |
| Mar 2011 | - | $3.90 M(-1.1%) | $21.48 M(-8.8%) |
| Dec 2010 | $23.54 M(-39.6%) | $3.94 M(-49.5%) | $23.54 M(-29.9%) |
| Sept 2010 | - | $7.80 M(+33.6%) | $33.58 M(-0.3%) |
| June 2010 | - | $5.84 M(-2.0%) | $33.67 M(-5.0%) |
| Mar 2010 | - | $5.96 M(-57.4%) | $35.43 M(-9.0%) |
| Dec 2009 | $38.94 M | $13.98 M(+76.9%) | $38.94 M(+4.3%) |
| Sept 2009 | - | $7.90 M(+4.0%) | $37.35 M(+7.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | $7.59 M(-19.8%) | $34.70 M(+8.7%) |
| Mar 2009 | - | $9.47 M(-23.6%) | $31.91 M(+16.8%) |
| Dec 2008 | $27.32 M(+111.8%) | $12.39 M(+136.1%) | $27.32 M(+32.0%) |
| Sept 2008 | - | $5.25 M(+9.2%) | $20.70 M(-1.1%) |
| June 2008 | - | $4.80 M(-1.4%) | $20.93 M(+19.4%) |
| Mar 2008 | - | $4.87 M(-15.5%) | $17.53 M(+36.0%) |
| Dec 2007 | $12.89 M(+224.2%) | $5.77 M(+5.3%) | $12.89 M(+81.0%) |
| Sept 2007 | - | $5.48 M(+288.6%) | $7.12 M(+333.1%) |
| June 2007 | - | $1.41 M(+500.0%) | $1.65 M(+26.7%) |
| Mar 2007 | - | $235.00 K(-77.9%) | $1.30 M(-103.2%) |
| Dec 2006 | $3.98 M(-61.1%) | - | - |
| June 2006 | - | $1.06 M(-63.5%) | -$41.11 M(-1235.1%) |
| Mar 2006 | - | $2.91 M(-103.8%) | $3.62 M(-90.4%) |
| Dec 2005 | $10.22 M(-90.9%) | -$77.09 M(-340.9%) | $37.69 M(-71.1%) |
| Sept 2005 | - | $32.00 M(-30.1%) | $130.44 M(+0.1%) |
| June 2005 | - | $45.80 M(+23.8%) | $130.37 M(+11.6%) |
| Mar 2005 | - | $36.98 M(+136.3%) | $116.84 M(-14.9%) |
| Dec 2004 | $112.11 M(+38.2%) | $15.65 M(-51.0%) | $137.27 M(+15.2%) |
| Sept 2004 | - | $31.93 M(-1.1%) | $119.21 M(+0.5%) |
| June 2004 | - | $32.27 M(-43.8%) | $118.56 M(+2.7%) |
| Mar 2004 | - | $57.41 M(-2478.4%) | $115.41 M(+42.3%) |
| Dec 2003 | $81.12 M(+13.0%) | -$2.41 M(-107.7%) | $81.12 M(-5.7%) |
| Sept 2003 | - | $31.28 M(+7.4%) | $85.98 M(+7.5%) |
| June 2003 | - | $29.13 M(+26.0%) | $79.97 M(+14.2%) |
| Mar 2003 | - | $23.12 M(+843.0%) | $70.01 M(-2.5%) |
| Dec 2002 | $71.77 M(-6.0%) | $2.45 M(-90.3%) | $71.77 M(-22.0%) |
| Sept 2002 | - | $25.27 M(+31.8%) | $91.96 M(+7.1%) |
| June 2002 | - | $19.17 M(-23.0%) | $85.87 M(+2.0%) |
| Mar 2002 | - | $24.89 M(+9.9%) | $84.19 M(+10.3%) |
| Dec 2001 | $76.34 M(+58.7%) | $22.64 M(+18.1%) | $76.34 M(+13.0%) |
| Sept 2001 | - | $19.17 M(+9.6%) | $67.53 M(+9.0%) |
| June 2001 | - | $17.49 M(+2.7%) | $61.95 M(+12.2%) |
| Mar 2001 | - | $17.04 M(+23.2%) | $55.23 M(+12.7%) |
| Dec 2000 | $48.11 M(+17.6%) | $13.83 M(+1.8%) | $49.01 M(+2.9%) |
| Sept 2000 | - | $13.59 M(+26.2%) | $47.61 M(+8.7%) |
| June 2000 | - | $10.77 M(-0.4%) | $43.78 M(+5.7%) |
| Mar 2000 | - | $10.82 M(-13.0%) | $41.41 M(+1.3%) |
| Dec 1999 | $40.90 M(+131.0%) | $12.43 M(+27.3%) | $40.89 M(+24.8%) |
| Sept 1999 | - | $9.77 M(+16.3%) | $32.77 M(+21.8%) |
| June 1999 | - | $8.40 M(-18.4%) | $26.90 M(+17.5%) |
| Mar 1999 | - | $10.30 M(+139.5%) | $22.90 M(+29.4%) |
| Dec 1998 | $17.70 M(-65.8%) | $4.30 M(+10.3%) | $17.70 M(-49.7%) |
| Sept 1998 | - | $3.90 M(-11.4%) | $35.20 M(-15.2%) |
| June 1998 | - | $4.40 M(-13.7%) | $41.50 M(-11.7%) |
| Mar 1998 | - | $5.10 M(-76.6%) | $47.00 M(-9.1%) |
| Dec 1997 | $51.70 M(+40.5%) | $21.80 M(+113.7%) | $51.70 M(+30.9%) |
| Sept 1997 | - | $10.20 M(+3.0%) | $39.50 M(+0.3%) |
| June 1997 | - | $9.90 M(+1.0%) | $39.40 M(+3.7%) |
| Mar 1997 | - | $9.80 M(+2.1%) | $38.00 M(+2.7%) |
| Dec 1996 | $36.80 M(+50.2%) | $9.60 M(-5.0%) | $37.00 M(+4.8%) |
| Sept 1996 | - | $10.10 M(+18.8%) | $35.30 M(+11.0%) |
| June 1996 | - | $8.50 M(-3.4%) | $31.80 M(+10.8%) |
| Mar 1996 | - | $8.80 M(+11.4%) | $28.70 M(+17.1%) |
| Dec 1995 | $24.50 M(+84.2%) | $7.90 M(+19.7%) | $24.50 M(+14.5%) |
| Sept 1995 | - | $6.60 M(+22.2%) | $21.40 M(+15.7%) |
| June 1995 | - | $5.40 M(+17.4%) | $18.50 M(+18.6%) |
| Mar 1995 | - | $4.60 M(-4.2%) | $15.60 M(+17.3%) |
| Dec 1994 | $13.30 M | $4.80 M(+29.7%) | $13.30 M(+56.5%) |
| Sept 1994 | - | $3.70 M(+48.0%) | $8.50 M(+77.1%) |
| June 1994 | - | $2.50 M(+8.7%) | $4.80 M(+108.7%) |
| Mar 1994 | - | $2.30 M | $2.30 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual revenue?
- What is the all time high annual revenue for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual revenue year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly revenue?
- What is the all time high quarterly revenue for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly revenue year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM revenue?
- What is the all time high TTM revenue for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM revenue year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual revenue?
The current annual revenue of LGND is $131.31 M
What is the all time high annual revenue for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual revenue is $251.45 M
What is Ligand Pharmaceuticals Incorporated annual revenue year-on-year change?
Over the past year, LGND annual revenue has changed by -$64.93 M (-33.09%)
What is Ligand Pharmaceuticals Incorporated quarterly revenue?
The current quarterly revenue of LGND is $51.81 M
What is the all time high quarterly revenue for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly revenue is $90.04 M
What is Ligand Pharmaceuticals Incorporated quarterly revenue year-on-year change?
Over the past year, LGND quarterly revenue has changed by +$18.94 M (+57.64%)
What is Ligand Pharmaceuticals Incorporated TTM revenue?
The current TTM revenue of LGND is $152.42 M
What is the all time high TTM revenue for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM revenue is $251.79 M
What is Ligand Pharmaceuticals Incorporated TTM revenue year-on-year change?
Over the past year, LGND TTM revenue has changed by -$1.17 M (-0.76%)